1
Modified adenoviral vectors for use in gene therapy. Introgene, March 14, 2001: EP1083229-A1 (1 worldwide citation)

The present invention provides means and methods for the generation and manufacturing of recombinant Ad vectors that are modified in E2B and/or E4 functions, preferably, said vectors comprise E1 and/or E2A deletions. For this purpose, the vector genome is modified in the respective promoter regions, ...


2
Schouten Govert Johan, Vogels Ronald, Opstelten Dirk Jan Elbertus: Modified adenoviral vectors for use in gene therapy. Introgene, March 14, 2001: EP1083228-A1

The invention provides a method for producing a recombinant adenovirus-like gene delivery vehicle having reduced expression of adenoviral E2B and/or E4 gene products in a target cell for gene therapy, comprising generating a recombinant adenoviral vector lacking E1A and preferably E1B sequences, but ...


3
Schouten Govert Johan, Vogels Ronald, Opstelten Dirk Jan Elbertus: Modified adenoviral vectors for use in gene therapy. Crucell Holland, Schouten Govert Johan, Vogels Ronald, Opstelten Dirk Jan Elbertus, PRINS A W, March 22, 2001: WO/2001/020014

The present invention provides means and methods for the generation and manufacturing of recombinant Ad vectors that are modified in E2B and/or E4 functions, preferably, said vectors comprise E1 and/or E2A deletions. For this purpose, the vector genome is modified in the respective promoter regions ...